BeOne Medicines Q2 FY26 GAAP diluted EPS rises 144% to $2.05 per ADS; revenue climbs 30% to $1.71 billion

Reuters2026/08/05 10:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BeOne Medicines posted Q2 revenue of USD 1.71 billion, up 30% year over year; GAAP diluted EPS per ADS rose to USD 2.05.
GAAP operating income surged to USD 325.05 million; GAAP net income more than doubled to USD 237.01 million.
GAAP gross margin expanded 3 percentage points to 90%; free cash flow climbed to USD 435.34 million.
BRUKINSA revenue rose to USD 1.2 billion, up 31%; TEVIMBRA increased to USD 229 million, up 18%.
Raised FY 2026 revenue outlook to USD 6.6-6.8 billion; GAAP operating income guidance lifted to USD 1-1.1 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202608050600BIZWIRE_USPR_____20260805_BW570642) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BeOne Medicines Q2 FY26 GAAP diluted EPS rises 144% to $2.05 per ADS; revenue climbs 30% to $1.71 billion

You may also like

Crypto prices